Next-Generation Sequencing (NGS) in Precision Medicine Market Report 2025

The next-generation sequencing (NGS) in precision medicine market size has grown rapidly in recent years. It will grow from $5.47 billion in 2024 to $6.42 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth observed during the historic period can be linked to increased government investment in genomics research, rising incidence of genetic disorders, expansion of national biobank initiatives, growing demand for targeted therapies and biomarker discovery, and the emergence of multi-omics platforms.

The next-generation sequencing (NGS) in precision medicine market size is expected to see rapid growth in the next few years. It will grow to $12.03 billion in 2029 at a compound annual growth rate (CAGR) of 17%. The growth projected for the forecast period can be attributed to rising demand for personalized medicine, broader applications beyond human genomics, increasing prevalence of cancer, expansion into non-communicable disease detection, and greater awareness and accessibility of genetic testing. Key trends during the forecast period include integration with next-generation sequencing, AI-enabled bioinformatics pipelines, incorporation of advanced imaging for improved diagnostics and treatment, innovations in sequencing chemistry, and the development of cloud-based bioinformatics solutions.

The increasing incidence of genetic disorders is expected to drive the growth of the next-generation sequencing (NGS) market in precision medicine. Genetic disorders are conditions caused by abnormalities in an individual's DNA, which can be inherited or result from mutations. Advances in diagnostic technologies, such as genetic screening and next-generation sequencing, have improved the ability to detect genetic disorders, leading to a higher reported prevalence. NGS plays a vital role in precision medicine by identifying genetic mutations, enabling accurate diagnoses, personalized treatments, and early interventions. For example, in May 2024, the National Health Service in the UK reported that around 17,000 people in England live with sickle cell disease, a genetic blood disorder, with approximately 250 new cases diagnosed annually. As the incidence of genetic disorders continues to rise, the demand for NGS in precision medicine is increasing.

Companies operating in the NGS precision medicine market are focusing on innovative solutions, such as multimodal DNA and RNA library kits, to improve the efficiency and accuracy of genomic analyses. These kits enable the simultaneous preparation of sequencing libraries from both DNA and RNA within a single workflow, allowing for comprehensive analysis of a sample’s genome and transcriptome. For instance, in May 2024, Qiagen N.V., a Germany-based provider of sample and assay technologies, launched the QIAseq Multimodal DNA and RNA Library Kit. This NGS solution supports multiomic studies by streamlining DNA and RNA library preparation from a single sample, reducing the need for large amounts of material and labor-intensive procedures associated with traditional separate workflows. By enhancing the efficiency of multiomic research, this kit supports precision medicine advancements, particularly in cancer research, by facilitating better biomarker discovery and disease understanding.

In June 2025, Qiagen N.V. partnered with Incyte Corporation, a U.S.-based biopharmaceutical company, to develop a multimodal NGS companion diagnostic panel for patients with myeloproliferative neoplasms (MPNs). This collaboration aims to create a diagnostic tool that identifies mutations in CALR and other genes associated with MPNs, helping guide patient selection for targeted therapies and improving treatment outcomes. By advancing precision medicine, this partnership supports the development of more effective treatments for MPN patients.

Major players in the next-generation sequencing (NGS) in precision medicine market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Natera Inc., Tempus Labs Inc., 10x Genomics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Fulgent Genetics Inc., Twist Bioscience Corporation, Pacific Biosciences of California Inc., Macrogen Inc., Ultima Genomics Inc., Personalis Inc., Element Biosciences Inc., Genomenon Inc., Strand Life Sciences Pvt. Ltd., and Singular Genomics Systems Inc.

North America was the largest region in the next-generation sequencing (NGS) in precision medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in next-generation sequencing (NGS) in precision medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the next-generation sequencing (NGS) in precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Next-generation sequencing (NGS) in precision medicine refers to a cutting-edge genomic technology that allows rapid and comprehensive analysis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequences at exceptional scale and speed, providing insights far beyond those offered by traditional sequencing approaches. It plays a central role in precision medicine by revealing detailed information on individual genetic variations and molecular profiles, supporting highly informed medical assessments and decisions.

The primary types of products and services in next-generation sequencing (NGS) in precision medicine include sequencing instruments, consumables and reagents, library preparation kits, bioinformatics software, and NGS services. Sequencing instruments are specialized devices used to decode the DNA or RNA sequences of biological samples. Technologies covered include whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, RNA sequencing, and single-cell sequencing. NGS is applied in fields such as oncology, infectious diseases, rare and inherited disorders, prenatal and reproductive health, and pharmacogenomics. Key end users include hospitals and clinics, academic and research institutions, biopharmaceutical companies, diagnostic laboratories, and contract research organizations (CROs).

The next-generation sequencing (NGS) in precision medicine market research report is one of a series of new reports that provides next-generation sequencing (NGS) in precision medicine market statistics, including next-generation sequencing (NGS) in precision medicine industry global market size, regional shares, competitors with a next-generation sequencing (NGS) in precision medicine market share, detailed next-generation sequencing (NGS) in precision medicine market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation sequencing (NGS) in precision medicine industry. This next-generation sequencing (NGS) in precision medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next-generation sequencing (NGS) in precision medicine market consists of revenues earned by entities by providing services such as whole genome sequencing, metagenomic sequencing, hereditary cancer screening, pharmacogenomics testing, and rare disease diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation sequencing (NGS) in precision medicine market also includes sales of sequencing instruments, reagents and consumables, bioinformatics software, data analysis tools, and sequencing panels and assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.